The Big Bet: Health Care Deal Spotlight for September 1 to 7, 2025)
Healthcare deal spotlight September 1 to 7, 2025
Shajini
NCPE Recommends Conditional Access for Omeprazole
NCPE recommends Omeprazole Appizped for reimbursement eligibility.
NCPE Recommends Vabysmo, Signaling Retinal Policy Shift
NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.
J&J Launches AI in Surgery Funding via Polyphonic™ Fund
J&J invests $100M in AI in surgery funding to drive smarter surgical solutions.
Stryker’s Incompass Total Ankle Wins FDA Clearance
Stryker FDA-cleared InCompass Ankle; protein degrader partnerships drive innovation.
Kymera Strikes License Agreement Deals With Sanofi, Gilead
Sanofi, Gilead sign License Agreement with Kymera for protein degrader programs.
Hereditary Angioedema Drug From CSL Gains German Backing
Hereditary angioedema therapy by CSL Behring gains positive nod in Germany.
FDA Import Ban Disrupts Olympus’ US Medical Supply
FDA import ban issued on Olympus medical devices from Japan for quality violations.
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
New Reimbursement Strategy Boosts Ambulatory Pay
New partnership advances reimbursement strategy for private practices.